CSBio CSBio

X
[{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Fosun Pharma Sign Exclusive License and Distribution Agreements For Aloxi\u00ae, Akynzeo\u00ae Oral, NEPA IV and Anamorelin in Mainland China, Hong Kong SAR and Macau SAR","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Fosun Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Techdow USA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Techdow USA and CTTQ Pharma Announce Collaboration Agreement and Launch of Fosaprepitant for Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Chia Tai Tianqing Pharmaceutical Group"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.

            Lead Product(s): Fosaprepitant

            Therapeutic Area: Gastroenterology Product Name: Emend-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Techdow USA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Anaprozole Sodium Enteric-coated Tablet is currently the first and only proton pump inhibitor, which is investigated for the treatment of duodenal ulcer.

            Lead Product(s): Anaprozole Sodium

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Adalimumab injection (UBP1211) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children has been approved by the National Medical Products Administration.

            Lead Product(s): Adalimumab

            Therapeutic Area: Gastroenterology Product Name: UBP1211

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Helsinn will grant Fosun an exclusive license to distribute, promote and sell the following products in the aforesaid territory: Aloxi (Palonosetron hydrochloride), Akynzeo (Netupitant and Palonosetron hydrochloride) and NEPA (Fosnetupitant and Palonosetron hydrochloride).

            Lead Product(s): Palonosetron

            Therapeutic Area: Gastroenterology Product Name: Aloxi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Helsinn Advanced Synthesis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 12, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY